Astrocytoma
86
14
21
37
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
16 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.1%
13 terminated out of 86 trials
74.0%
-12.5% vs benchmark
6%
5 trials in Phase 3/4
43%
16 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (86)
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Tuvusertib in Astrocytoma With ATRX Mutation
Pediatric Long-Term Follow-up and Rollover Study
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Venous Thromboembolism Prevention in Outpatients With Glioma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
FearLess in NeuroOncology
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
Implantable Microdevice In Primary Brain Tumors
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma